Latest News

FDA proposes ban on hair straightener ingredients


 

The Food and Drug Administration is considering banning chemicals used in hair straightening products that have been linked to cancer.

The proposal specifies that formaldehyde would be banned, as well as other chemicals that release formaldehyde, such as methylene glycol. Using hair smoothing products containing formaldehyde and formaldehyde-releasing chemicals “is linked to short-term adverse health effects, such as sensitization reactions and breathing problems, and long-term adverse health effects, including an increased risk of certain cancers,” the proposal states.

One study published last year showed that repeated use of hair straightening products, also called relaxers, could more than double the risk of uterine cancer. Although that study didn’t find that the uterine cancer risk varied based on a person’s race, the researchers noted that women who are Black are among the most likely to use the products and tend to start using them at younger ages, compared with people of other races and ethnicities.

Hair straightening products have also been linked to elevated risks of hormone-sensitive cancers, such as breast cancer and ovarian cancer.

Rep. Ayanna Pressley (D-Mass.) and Rep. Shontel Brown (D-Ohio) applauded the proposed rule in a statement issued jointly on Oct. 6. “The FDA’s proposal to ban these harmful chemicals in hair straighteners and relaxers is a win for public health – especially the health of Black women who are disproportionately put at risk by these products as a result of systemic racism and anti–Black hair sentiment,” Rep. Pressley said The two congresswomen wrote a letter to the FDA earlier this year requesting the topic be investigated.

“Regardless of how we wear our hair, we should be allowed to show up in the world without putting our health at risk. I applaud the FDA for being responsive to our calls and advancing a rule that will help prevent manufacturers from making a profit at the expense of our health,” Rep. Pressley said in the statement. “The administration should finalize this rule without delay.”

A version of this article appeared on WebMD.com

Recommended Reading

FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
MDedge Internal Medicine
Does Ozempic cause hair loss?
MDedge Internal Medicine
Low-dose oral minoxidil for hair loss soars after NYT article
MDedge Internal Medicine
Hairy moles may contain the cure for baldness: Study
MDedge Internal Medicine
Free teledermatology clinic helps underserved patients initiate AD care
MDedge Internal Medicine
Black women weigh emerging risks of ‘creamy crack’ hair straighteners
MDedge Internal Medicine
Study aims to better elucidate CCCA in men
MDedge Internal Medicine
Low-dose oral minoxidil for female pattern hair loss: Benefits, impact on BP, heart rate evaluated
MDedge Internal Medicine
European Commission grants approval of ritlecitinib for severe alopecia areata
MDedge Internal Medicine
Most adults with alopecia areata untreated 1 year after diagnosis
MDedge Internal Medicine